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Abstract
Objective: To determine, “Is clofibrate a safe and effective adjunctive treatment to phototherapy
for neonatal jaundice?”
Study Design: Review of three English language, randomized controlled trials (one of which
was double-blind) published between 2005-2009.
Data sources: Randomized controlled clinical trials comparing a one-time oral dose of
clofibrate (100 mg/kg) plus phototherapy compared to phototherapy alone were found using
Cochrane and EBSCOhost.
Outcomes Measured: The outcomes in all three studies were duration of phototherapy
(measured in hours) and the safety of clofibrate (measured by the report of side effects at followup).
Results: All three trials demonstrated that the one-time dose of oral clofibrate (100 mg/kg) in
addition to photherapy significantly decreases the duration of photherapy needed for the
treatment of neonatal jaundice. Follow-up arrangements were made for two days, one week and
one month for the Mohammadzadeh, Sakha, and Badeli trials respectively. Two studies had no
reported side effects noted at follow-up, but the Sakha trial noted an episode of rebound
increases in bilirubin levels in an infant in the control group.
Conclusions: Clofibrate is an effective adjunctive treatment when combined with phototherapy
for treatment of neonatal jaundice. However, longer follow-up studies are needed to determine
the true safety of the drug and the incidence of any long-term sequelae.
Key Words: clofibrate, Atromid-S, neonatal jaundice.

Introduction
Neonatal jaundice is a common problem among newborns. In fact, up to 60% of fullterm and 80% of pre-term newborns worldwide are diagnosed with jaundice within the first
seven days of life.4 The term „jaundice‟ is generally characterized by a visible “yellowing” of
the skin. Once jaundice is noted in an infant, the severity of the condition is then determined by
a blood test (total serum bilirubin) to determine if treatment is necessary. Bilirubin is an endproduct of red cell breakdown in the body (this is called „indirect‟ bilirubin). In a normal infant,
the „indirect‟ bilirubin in the blood is converted into „direct‟ bilirubin in the liver. Direct
bilirubin is then excreted in the stool via the gut. However, when the „indirect‟ bilirubin is not
efficiently converted into „direct‟ bilirubin it accumulates in the body leading to the “yellow”
color characteristic of jaundice. Although many cases of newborn jaundice do not cause
permanent damage, severe cases that are not treated quickly can lead to a brain damage referred
to as, “kernicterus” which can lead to life-long complications.5
The cost to treat neonatal jaundice can vary greatly from one infant to another depending
on the severity of the condition. For those with mild jaundice, the practitioner may choose to
check the infant a couple times per week in the office to ensure the issue is resolving. In
moderate to severe cases, it is likely that the newborn will need to be treated with phototherapy.
For those newborns whose condition requires in-patient treatment, it is likely that an extensive
hospital bill will accrue due to phototherapy machines, monitors, and tests essential for tracking
the condition.
The high incidence of neonatal jaundice explains how important this condition is to
practitioners. Physician assistants in family medicine, pediatrics, emergency medicine and

internal medicine are likely to be exposed to cases of neonatal jaundice during their career. In
addition, it is critical that practitioners have an understanding of the available treatments for
neonatal jaundice, as this disease can be time-critical if the condition is severe.
Currently, the mainstay of treatment of neonatal jaundice is phototherapy where the
infant is put in an incubator and exposed to lights, which helps the body excrete the excess
bilirubin into the stool. This form of therapy is effective, however, improvement takes days and
can lead to dangerous side effects such as retinal damage, hyperthermia (or increased body
temperature), and diarrhea.1 Although precautions are taken to ensure that side effects are
minimal (such as covering the infants eyes during treatment) there is still a possibility of danger.
In severe cases of neonatal jaundice, an exchange transfusion (remove blood and related products
from the body and replace them with products from a donor) may be indicated to help prevent
kernicterus.3 Other possible interventions include medications such as Phenobarbital, Dpenicillamine, and oral charcoal, but these treatments are not widely used and are still being
researched for efficacy.1 Clofibrate (brand name Atromid-S) is another drug treatment being
researched, but it is not considered an alternative to phototherapy. Instead, it is thought that by
adding a single dose of oral clofibrate (100 mg/kg) to the phototherapy treatment the duration of
phototherapy needed would be decreased (because clofibrate helps indirect bilirubin convert to
direct bilirubin).2
Objective
The objective of this limited systematic review is to determine, “Is clofibrate a safe and
effective adjunctive treatment to phototherapy for neonatal jaundice?”

Method
A thorough search was conducted by the author using the Cochrane Database of
Systematic Reviews and Clinical Trials as well as EBSCOhost. All studies were published in
English, located in peer-reviewed journals, and dated between 2005-2009. The key words used
to search for studies were “clofibrate,” “Atromid-S,” and “neonatal jaundice.” The three studies
utilized for this limited systematic review included newborns born either at term (38-41 weeks)
or late pre-term (34-37 weeks) diagnosed with neonatal jaundice and admitted to the hospital
(specifically those with a serum bilirubin between 15-29.9 mg/dl). The studies all used the same
intervention of a single dose of oral clofibrate 100 mg/kg as an adjunct to phototherapy. These
intervention groups were compared to control groups, which only received phototherapy. The
main outcomes measured were the effect on jaundice (measured by duration of phototherapy)
and the safety of clofibrate (measured by reported side effects). Both of the outcomes measured
are patient oriented evidence that matters (POEM). All of the studies were randomized
controlled trials (one of which was double-blind).
The inclusion criteria for the studies were as follows: born at term (38-41 weeks) or late
pre-term (34-37 weeks), breastfed, serum bilirubin between 15-29.9 mg/dl, and body weight
between 2500-4000g. The exclusion criteria for the studies were as follows: congenital
abnormalities, G6PD deficiency, infection, dehydration, and hemolytic disorders (such as ABO
or Rh incompatibility). Table 1 includes the demographics for the studies utilized. Statistics
reported include p-values with confidence intervals (CI), numbers needed to treat (NNT), relative
risk reduction (RRR), absolute risk reduction (ARR).

Results: Table of demographics of included studies (Table 1)
Study

Type

#
Pts

Age
(years)

Inclusion Criteria

Exclusion Criteria

38-41
weeks

breastfed, serum
bilirubin between
15-29.9 mg/dl;
body wt between
2500-4000g

dehydration; infection; ABO
or Rh incompatibility; G6PD
deficiency; conjugated
bilirubin >15% of total serum
bilirubin; congenital
anomalies

38-41
weeks

breastfed; serum
bilirubin 17-29.9
mg/dl; healthy

congenital anomalies;
hemolytic disease; infection;
dehydration; G6PD
deficiency; conjugated
bilirubin >15% of total serum
bilirubin

34-37
weeks

non-hemolytic
jaundice; no need
for exchange
transfusion

congenital anomalies;
hemolytic disorders; G6PD
deficiency; sepsis or
significant accompanying
illness

W/D

Interventions

0

phototherapy
VS.
phototherapy +
clofibrate (100
mg/kg x1 dose)

0

phototherapy
VS.
phototherapy +
clofibrate (100
mg/kg x1 dose)

0

phototherapy
VS.
phototherapy +
clofibrate (100
mg/kg x1 dose)

Badeli, Iran

RCT

90

Mohammadzadeh, India

RCT

60

Sakha, India
Double blind
RCT

68

Outcomes Measured
The primary outcomes measured in all three studies were duration of phototherapy
(measured in hours) and the safety of clofibrate, both of which are POEMs. The safety of
clofibrate was measured by the side effects reported by parents at follow-up after the infant was
discharged home.
Results
The results pertaining to the duration of phototherapy were presented in continuous data
as hours of phototherapy endured by the patients. The data was then presented in the articles as a
mean number of hours of phototherapy needed with the standard deviations (SD) also included
(Table 2). For ease of communication, this limited systematic review will refer to the study

Results: Efficacy of Clofibrate + Phototherapy on Duration of Phototherapy (Table 2)
Phototherapy duration (hours)- mean +/- SD

Range/CI (hours)

P-value

Clofibrate

Control

Clofibrate

Control

Badelli, 2008

38.8 +/- 7.5

68.75 +/- 15.4

20-48

36-96

< 0.001

Mohammadzadeh, 2005

30 +/- 12.89

54 +/- 18.83

12-48.

24-96

< 0.0001

64.32 +/- 12.48

87.84 +/- 29.76

CI= 60-81.6

CI= 79.2-108

< 0.001

Sakha, 2009

SD= standard deviation; CI- confidence interval

groups as control (phototherapy only) or clofibrate (phototherapy + 100 mg/kg of clofibrate x1
dose). For the Badelli, 2008 study the infants in the clofibrate group needed an average of 38.8
hours (SD=7.5; range 20-48) of phototherapy while the control group required 68.75 hours
(SD=15.4; range 36-96), which was a significant difference (p<0.001). The Mohammadzadeh,
2005 study also had a significant difference in phototherapy duration (p<0.0001); the clofibrate
group requiring a mean of 30 hours (SD=12.89; range 12-48) and the control group 54 hours
(SD=18.83; range 24-96). The newborns in the Sakha, 2009 clofibrate group received an
average of 64.32 hours (SD=12.48; CI=60-81.6), while the control received 87.84 (SD=29.76;
CI=79.2-108); this finding is significant (p<0.001).
The results for the incidence of side effects are summarized in Table 3. For both the
Badelli, 2008 and the Mohammadzadeh, 2005 studies there were no adverse effects reported at
follow-up for any of the participants regardless of the group they were in (control versus
clofibrate). However, the Sakha, 2009 trial had one incidence of rebound increases in bilirubin
levels (called rebound hyperbilirubinemia); the patient was a member of the control group. The
RRR and ARR were calculated to be 1% and 0.03% respectively. Number needed to treat
(NNT) was deemed to be -33 with the one-time oral clofibrate dose of 100 mg/kg.

Results: Safety of Clofibrate as measured by side effects (Table 3)
% of pts in control
group with side effects

% of pts in study
group with side effects

RRR

ARR

NNT

Badelli, 2008

0

0

0

0

0

Mohammadzadeh, 2005

0

0

0

0

0

0.03%

0

-1%

-0.03%

-33*

Study

Sakha, 2009

SE= side effects; RRR= relative risk reduction; ARR= absolute risk reduction; NNT= numbers needed to treat
* Since the outcome measured here is the incidence of side effects, the negative NNT means that for every 33
patients who received clofibrate there was 1 less incidence of reported side effects than those who received
phototherapy alone.

Discussion
All three of the studies contained in this limited systematic review demonstrated a
significantly lower duration of phototherapy needed for infants who received the one-time dose
of clofibrate in addition to phototherapy (clofibrate group) when compared to newborns who
received phototherapy alone (control group). In addition, the newborns in the control group
required an average of at least twenty-three additional hours of treatment with phototherapy
before meeting qualifications for discharge when compared to the clofibrate group. These results
show that the hospital stay for newborns requiring treatment for jaundice can be decreased by a
minimum of one day by simply adding a one-time dose of clofibrate.
The studies also seem to indicate that clofibrate is a safe drug to use in infants. Each
study arranged a follow-up appointment to determine if parents noted any side effects. The
Mohammadzdeh, 2005 study had the quickest follow-up at 2 days, while the Sakha, 2009 and
Badeli, 2008 studies followed up at one week and one month respectively. Although there were
no reports of side effects at follow-up, it is not enough to deem the use of clofibrate safe due to
the history of the drug.

Clofibrate was originally used to treat high cholesterol and was taken at a dose of 500 mg
per day by adults. However, after studies demonstrated an increased mortality rate during active
use of the drug in the 1980‟s, its production was discontinued in the United States. In spite of
this, studies also indicated mortality rates decrease significantly after termination of use.6
Therefore, it is possible that the use of clofibrate may be completely safe for use in the treatment
of neonatal jaundice as it is only a one-time dose and not a continuing medication regimen.
Nevertheless, the studies in this limited systematic review did not follow-up nearly long enough
to rule out long-term sequelae, which makes this a huge limitation to these studies.
Another limitation is the fact that each study used a different technique of administering
phototherapy. The Sakha, 2009 trial utilized units containing eight blue fluorescent tubes
situated at 20-cm above the infant. The Mohammadzadeh, 2005 trial also situated the lights 20cm above the infant, but used six white lamps instead of the blue used in the Sakha, 2009 trial.
Finally, the Badeli, 2008 trial used four white lights positioned 30-cm above the newborn.
Although the results in each trial demonstrated a decreased phototherapy time with clofibrate, the
results would be more convincing with the same phototherapy technique used among the studies.
In addition, it is possible that the difference in lights may have had an effect on the outcome of
the studies.
Conclusion
Clofibrate is an effective adjunctive treatment when combined with phototherapy for
treatment of neonatal jaundice. However, longer follow-up on patients and further research on
long-term effects of the drug on the infant is needed to get this drug approved by the FDA for
use in the United States.
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